

STATEMENT BY APPLICANT				10/023,909		
				12/18/01		
				APPLICANT: Heather L. Davis et al.		
Sheet 1 of 3				GROUP ART UNIT: 1648		EXAMINER: Jeffrey S. Parkin

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>[Signature]</i>	A1	6,194,388	B1	Krieg et al.	02-27-2001
	A2	6,207,646	B1	Krieg et al.	03-27-2001
	A3	6,214,806	B1	Krieg et al.	04-10-2001
	A4	6,218,371	B1	Krieg et al.	04-17-2001
	A5	6,225,292	B1	Raz et al.	05-01-2001
	A6	6,239,116	B1	Krieg et al.	05-29-2001
	A7	6,339,068		Krieg et al.	01/15/2002
	A8	6,406,705	B1	Davis et al.	06-18-2002
	A9	6,429,199	B1	Krieg et al.	08-06-2002
	A10	6,498,148	B1	Raz	12/24/2002
	A11	6,514,948	B1	Raz, et al	02/04/2003
	A12	6,534,062	B2	Krieg, et al.	03/18/2003
	A13	6,552,006	B2	Raz et al.	04/22/2003
	A14	6,562,798	B1	Schwartz	05/13/2003
	A15	6,589,940	B1	Raz et al.	07/08/2003
	A16	6,610,661	B1	Carson et al.	08/26/2003
	A17	6,653,292	B1	Krieg et al.	11/25/2003
	A18	US 2001/0046967		Van Nest	11/29/2001
	A19	US 2002/0028784		Van Nest	03/11/2002
	A20	US 2002/0042387		Raz et al.	04/11/2002
	A21	US 2002/0055477	A1	Nest et al	05/09/2002
	A22	US 2002/0086839		Raz et al.	07/04/2002
	A23	US 2002/0098199	A1	Van Nest et al.	07/25/2002
	A24	US 2002/0107212	A1	Van Nest et al.	08/08/2002
	A25	US 2002/0142978	A1	Raz et al.	10/03/2002
	A26	US 2002/0156033	A1	Bratzler et al.	10/24/2002
	A27	US 2003/0022852		Van Nest et al.	1/30/2003
	A28	US 2003/0049266	A1	Fearon et al.	03/13/2003
	A29	US 2003/0050263	A1	Krieg et al.	03/13/2003
	A30	US 2003/0059773		Van Nest et al.	01/30/2003
	A31	US 2003/0064064		Dina	04/03/2003
	A32	US 2003/0078223	A1	Raz et al.	04/24/2003
	A33	US 2003/0092663	A1	Raz	05/15/2003
	A34	US 2003/0109469	A1	Carson et al	06/12/2003
	A35	US 2003/0119773	A1	Raz et al.	06/26/2003
	A36	US 2003/0125284		Raz et al.	07/03/2003

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				10/023,909.		
				FILING DATE: 12/18/2001	CONFIRMATION NO.: 8458	
				APPLICANT: Heather L. Davis et al.		
				GROUP ART UNIT: 1648	EXAMINER: Jeffrey S. Parkin	
Sheet	2	of	3			

#### U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
J. [Signature]	A37	US 2003/0129251	A1	Van Nest et al.	07/10/2003
	A38	US 2003/0130217		Raz et al.	07/10/2003
	A39	US 2003/0133988	A1	Fearon et al.	07/17/2003
	A40	US 2003/0143213	A1	Raz et al.	07/37/2003
	A41	US 2003/0147870	A1	Raz et al.	08/07/2003
	A42	US 2003/0175731	A1	Fearon et al.	09/18/2003
	A43	US 2003/0176373		Raz et al.	09/18/2003
	A44	US 2003/0186921	A1	Carson et al.	10/02/2003
	A45	US 2003/0199466	A1	Fearon et al.	10/23/2003
	A46	US 2003/0203891		Goebel et al.	10/30/2003
	A47	US 2003/0212028	A1	Raz et al.	11/13/2003
	A48	US 2003/0216340	A1	Van Nest et al.	11/20/2003
	A49	US 2003/0232780		Carson et al.	12/18/2003
	A50	US 2004/0006034		Raz et al.	01/08/2004
	A51	US 2004/0009942		Van Nest et al.	01/15/2004

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
J. [Signature]	B1	WO	99/11275	A2	Regents of the University of CA	03/11/1999	
	B2	WO	99/62923	A2	Dynavax Tech. Corp	12/09/1999	
	B3	WO	00/20039	A1	Regents of the University of CA	04/13/2000	
	B4	WO	00/62787	A1	Regents of the University of CA	10/26/2000	
	B5	WO	98/55609	A1	Regents of the University of CA	10/12/1998	
	B6	WO	00/21556	A1	Dynavax Tech. Corp	04/20/2000	
	B7	WO	01/02007	A1	Regents of the University of CA	01/11/2001	
	B8	WO	01/12223	A2	Dynavax Tech. Corp	02/01/2001	
	B9	WO	01/55341	A2	Regents of the University of CA	08/02/2001	
	B10	WO	01/68077	A2	Dynavax Tech. Corp	09/20/2001	
	B11	WO	01/68078	A2	Dynavax Tech. Corp	09/20/2001	
	B12	WO	01/68103	A2	Dynavax Tech. Corp	09/20/2001	
	B13	WO	01/68116	A2	Dynavax Tech. Corp	09/20/2001	
	B14	WO	01/68117	A2	Dynavax Tech. Corp	09/20/2001	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				10/023,909	
				FILING DATE: 12/18/2001	CONFIRMATION NO.: 8458
				APPLICANT: Heather L. Davis et al.	
				GROUP ART UNIT: 1648	EXAMINER: Jeffrey S. Parkin
Sheet	3	of	3		

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	Elkins, K. L., Rhinehart-Jones, T. R., et al., "Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria." <i>J Immunol</i> 162:2291-2298, 1999.	
	C2	Freidag, B. L et al., "CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis." <i>Infect Immun</i> 68:2948-2953, 2000.	
	C3	Hayashi, T. et al., "Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase." <i>Infect Immun</i> 69:6156-6164, 2001.	
	C4	Juffermans, N. P. et al., "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis." <i>Infect Immun</i> 70:147-152, 2002.	
	C5	Klinman, D. M. et al., "Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection." <i>Infect Immun</i> 67:5658-5663, 1999"	
	C6	Klinman, D. M., et al. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. <i>Springer Semin Immunopathol</i> 22:173-183, 2000	
	C7	Krieg, A. M., et al., "CpG motifs in bacterial DNA and their immune effect." <i>Annu Rev Immunol</i> 20:709-760, 2002.	
	C8	Lipford, G. B. et al. "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines." <i>Eur J Immunol</i> 27:3420-3426, 1997.	
	C9	Sedegah, M. et al. "Interleukin 12 induction of interferon g-dependent protection against malaria." <i>Proc Natl Acad Sci U S A</i> 91:10700-10702, 1994.	
	C10	Sethi, S. et al. "Postexposure prophylaxis against prion disease with a stimulator of innate immunity." <i>Lancet</i> 360:229-230, 2002.	
	C11	Stacey, K. J et al. "Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major." <i>Infect Immun</i> 67:3719-3726, 1999	
	C12	Walker, P. S. et al. "Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-g-dependent mechanisms." <i>Proc Natl Acad Sci U S A</i> 96:6970-6975, 1999.	
	C13	Zimmermann, S. et al., "CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis." <i>J Immunol</i> 160:3627-3630, 1998.	

EXAMINER	DATE CONSIDERED 06/13/04
----------	-----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]